1

CLAIM AMENDMENTS

1 through 14 (canceled)

15. (new) A compound of the formula (I)

$$R$$
 $N \rightarrow 0$
 $N \rightarrow 0$

- 3 wherein
- R is a lower alkyl group or a group of the formula-NH-R1, wherein
- 5 R1 is a lower alkyl or a lower cycloalkyl group), or a
- 6 pharmaceutically acceptable acid addition salt thereof.
- 16. (new) The compound of the formula (I) as defined in
- claim 15, wherein R is C₁ to C₄ alkyl, or a pharmaceutically
- 3 acceptable acid addition salt thereof.
- 17. (new) The compound of the formula (I) as defined in
- claim 16, wherein R is methyl or ethyl, or a pharmaceutically
- acceptable acid addition salt thereof.

- 18. (new) The compound of the formula (I) as defined in claim 1, wherein R is a group of the formula-NH-R¹, and R¹ is a C_1 to C_4 alkyl or a C_3 to C_6 cycloalkyl group, or a pharmaceutically acceptable acid addition salt thereof.
- 19. (new) The compound of the formula (I) as defined in
 claim 18, wherein R¹ is a methyl or a cyclopropyl group, or a
 pharmaceutically acceptable acid addition salt thereof.
- 20. (new) The compound of the formula (I) as defined in claim 15, selected from the group consisting of:
- 3 (a) 1-(4-amino-3-methylphenyl)-8-chloro-4-methyl-3H-2,3-4 benzodiazepine 3-carboxylic acid methyl amide;
- 5 (b) 1-(4-amino-3-methylphenyl)-8-chloro-4-methyl-3H-2,3-6 benzodiazepine-3-carboxylic acid cyclopropyl amide;
- 7 (c) 3-acetyl-1-(4-amino-3-methylphenyl)-8-chloro-4-8 methyl-3H-2,3-benzodiazepine; and
- 9 (d) 3-propionyl-1-(4-amino-3-methylphenyl)-8-chloro-10 4-methyl-3H-2,3-benzodiazepine, or a pharmaceutically acceptable 11 acid addition salt thereof.

21. (new) A process for the preparation of a compound of the formula (I)

$$R$$
 $N \rightarrow 0$ $N \rightarrow 0$ $N \rightarrow 0$ $N \rightarrow 0$ $N \rightarrow 0$

wherein

3

11

- R is a C₁ to C₆ alkyl group or a group of the formula -NH-
- 6 R¹, wherein
- R^1 is a C_1 to C_6 alkyl or a C_3 to C_7 cycloalkyl group, or a
- pharmaceutically acceptable acid addition salt thereof, which
- 9 comprises
- 10 (a) reducing a compound of the formula (II),

$$CI$$
 N
 O
 NO_2
 (II)

16

- wherein R is as stated above; or
- for the preparation of a compound of the formula
- (I) wherein R is specifically a group of the formula-NH-R1, wherein
- 15 R¹ is as stated above,
 - (b) reacting a compound of the formula (IV),

- wherein Y is a lower alkyl group or a leaving
- group, with a compound of the formula (V),

 $H_2N-R^1 \quad (V)$

- wherein R¹ is as stated above,
- and, if desired, converting the compound of the formula (I) thus
- obtained into a pharmaceutically acceptable acid addition salt
- thereof.

- 22. (new) A pharmaceutical composition for treating a
 central nervous system disorder comprising as active ingredient a
 therapeutically effective amount of the compound of the formula (I)
 as defined in claim 15 or a pharmaceutically acceptable acid
 addition salt thereof in admixture with an inert solid or liquid
 carriers and/or auxiliary agent.
- 23. (new) A method of treating a patient suffering from a central nervous system disorder, which comprises the step of administering to said patient in need of such treatment, a therapeutically effective amount of the compound of the formula (I) as defined in claim 15 or a pharmaceutically acceptable acid addition salt thereof.

24. (new) A compound of the formula (II)

$$CI$$
 N
 O
 NO_2
 (II)

- wherein R is a lower alkyl group or a group of the formula-NH-R1,
- 4 wherein

1

2

3

3

- 5 R1 is a lower alkyl or a lower cycloalkyl group), or a
- 6 pharmaceutically acceptable acid addition salt thereof.

25. A compound of the formula (VIII)

wherein Y is a leaving group.

26. (New) A process for the preparation of a compound of the formula (II)

$$R$$
 CI
 N
 O
 NO_2
 (II)

4 wherein

12

- R is a lower alkyl group or a group of the formula-NH-R1, wherein
- 6 R1 is a lower alkyl or a lower cycloalkyl group), or a
- pharmaceutically acceptable acid addition salt thereof , which
- s comprises reacting a compound of the formula (VII)

with a reagent capable of introducing a Y group, and reacting the

thus-obtained compound of the formula (VIII)

- 8 -

with a compound of the formula (V)

14

H₂N-R1

(V)

to obtain the desired product.